Fresh Tracks Therapeutics Inc (OTCPK:FRTX)

$ 0.74 -0.005 (-0.67%) Market Cap: 4.45 Mil Enterprise Value: -4.51 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 52/100

Q3 2022 Fresh Tracks Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$1.77 (+2.31%)

Earnings
Q2 2022 Brickell Biotech Inc Earnings Call Transcript
Aug 11, 2022

$3.27 (-10.66%)

Earnings
Q1 2022 Brickell Biotech Inc Earnings Call Transcript
May 12, 2022

$9.31 (+3.45%)

Earnings
Q4 2021 Brickell Biotech Inc Earnings Call Transcript
Mar 15, 2022

$9.84 (-7.96%)

Earnings
Q3 2021 Brickell Biotech Inc Earnings Call Transcript
Nov 09, 2021

$18

Earnings
Brickell Biotech Inc Topline Results from Phase 3 Pivotal Cardigan Call Transcript
Oct 07, 2021
Brickell Biotech Inc Key Opinion Leader Webinar on DYRK1A Transcript
Sep 24, 2021
Brickell Biotech Inc and Voronoi Inc License Agreement Call Transcript
Sep 01, 2021
Q2 2021 Brickell Biotech Inc Earnings Call Transcript
Aug 12, 2021

$31.13 (+4.82%)

Earnings
Q1 2021 Brickell Biotech Inc Earnings Call Transcript
May 13, 2021

$38.25 (-2.30%)

Earnings
Brickell Biotech Inc Long Term Safety Study Results for Sofpironium Bromide Gel Corporate Call Transcript
Apr 23, 2021
Q4 2020 Brickell Biotech Inc Earnings Call Transcript
Mar 09, 2021

$54.9 (+7.02%)

Earnings
Q2 2020 Brickell Biotech Inc Earnings Call Transcript
Aug 12, 2020

$40.01 (+0.54%)

Earnings
Q1 2020 Brickell Biotech Inc Earnings Call Transcript
May 13, 2020

$63.45 (+13.25%)

Earnings
Q4 2019 Brickell Biotech Inc Earnings Call Transcript
Mar 18, 2020

$51.3 (-10.94%)

Earnings
Brickell Biotech, Inc., Vical Incorporated - M&A Call Transcript
Jun 03, 2019

Brickell Biotech Inc Key Opinion Leader Webinar on DYRK1A Transcript

Sep 24, 2021 / 02:00PM GMT

Release Date Price: $33.08 (+0.64%)

Transcript

Operator

Good morning, and welcome to the KOL webinar focused on the novel DYRK1A target and its role in autoimmunity hosted by Brickell Biotech. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay will be made available on the Brickell Biotech website following the conclusion of the event.

Turning to Slide 2. This presentation contains forward-looking statements. Please reference this slide and our recent SEC filings for additional disclosures of risks and uncertainties. I would now like to turn the call over to Dr. Monica Luchi, Brickell's Chief Medical Officer, for a brief introduction.

Monica E. Luchi

Brickell Biotech, Inc. - Chief Medical Officer

Thank you, Sarah. I'd like to thank everyone for joining the call today. We'll go to the next slide, please.

Homeostasis, or balance of the immune system, is the ideal in healthy individuals. When that balance is disrupted, excess inflammation, sometimes against self, may result. Inhibition of DYRK1A enhances regulatory T cell differentiation and decreases MyD88 and IRAK4

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.